BIOMAT Database Logo BIOMAT Database Logo

Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid. 1991

S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Drug Development Laboratory, University of South Alabama, Mobile 36688.

Structural modifications at the pyrimidine ring and at the C9,N10-bridge region of the thymidylate synthase (TS) inhibitors N10-propargyl-5,8-dideazafolate (1; PDDF; CB 3717), 2-desamino-N10-propargyl-5,8-dideazafolate (2, DPDDF), and 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolate (3, DMPDDF) have been carried out. Methods for the synthesis of 2-desamino-N10-propargyl-1,5,8-trideazafolate (4), 2-desamino-2-methyl-N10-propargyl-3,5,8-trideazafolate (5a), and 2-desamino-2-methyl-N10-propargyl-5,8-dideaza-1,2-dihydrofolate (6) have been developed. The bridge-extended analogues isohomo-PDDF (7) and isohomo-DMPDDF (8) contain an additional methylene group interposed between N10 and the phenyl ring of 1 and 3, respectively. All new compounds were evaluated as inhibitors of TS and the growth of tumor cells in culture. Selected analogues were tested as substrates of folylpolyglutamate synthetase (FPGS) and striking differences in substrate activity were observed among these compounds, indicating that structural modifications at the pyrimidine ring of classical antifolates profoundly influence their polyglutamylation. Enzyme inhibition data established that both N1 and N3-H of the pyrimidine ring are essential for efficient binding of quinazoline-type antifolates to human TS.

UI MeSH Term Description Entries
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D005492 Folic Acid A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. Pteroylglutamic Acid,Vitamin M,Folacin,Folate,Folic Acid, (D)-Isomer,Folic Acid, (DL)-Isomer,Folic Acid, Calcium Salt (1:1),Folic Acid, Monopotassium Salt,Folic Acid, Monosodium Salt,Folic Acid, Potassium Salt,Folic Acid, Sodium Salt,Folvite,Vitamin B9,B9, Vitamin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D013940 Thymidylate Synthase An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45. Thymidylate Synthetase,Synthase, Thymidylate,Synthetase, Thymidylate
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds.
June 1989, Journal of medicinal chemistry,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.
February 1988, European journal of cancer & clinical oncology,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Folate analogues. 30. Synthesis and biological evaluation of N10-propargyl-5,8-dideaza-5,6,7,8-tetrahydrofolic acid and related compounds.
July 1987, Journal of medicinal chemistry,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Folate analogues. 21. Synthesis and antifolate and antitumor activities of N10-(cyanomethyl)-5,8-dideazafolic acid.
April 1983, Journal of medicinal chemistry,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
January 1991, Journal of cancer research and clinical oncology,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Folate analogues. 26. Syntheses and antifolate activity of 10-substituted derivatives of 5,8-dideazafolic acid and of the poly-gamma-glutamyl metabolites of N10-propargyl-5,8-dideazafolic acid (PDDF).
September 1986, Journal of medicinal chemistry,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.
April 1988, European journal of cancer & clinical oncology,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717).
January 1985, Cancer chemotherapy and pharmacology,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
August 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S W Li, and M G Nair, and D M Edwards, and R L Kisliuk, and Y Gaumont, and I K Dev, and D S Duch, and J Humphreys, and G K Smith, and R Ferone
Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
November 1988, Biochemical pharmacology,
Copied contents to your clipboard!